Roche will receive exclusive global rights to ZW209 for $55 million upfront, a $40 million Phase 1b milestone, up to $718 million in further milestones and royalties, pending HSR clearance.
UK biotech venture capital hit £2.84bn in nine months of 2026. See the Q3 deals, the seed slump and what BIA wants from the Budget.
In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...
For much of the past decade, exosomes have occupied a familiar place in biotechnology: scientifically intriguing, biologically versatile and full of potential, but still some distance from becoming routinely manufactured products. That is beginning to change as...
Ilofotase alfa now belongs to Ambrose Healthcare after a deal worth up to €161 million for AM-Pharma. The terms, the data and the HPP rivals.
RNA delivery research is moving beyond conventional lipid nanoparticle (LNP) formulation toward a more systematic understanding of how lipid chemistry, particle organization, and intracellular trafficking influence delivery performance. As researchers confront...
As transcatheter aortic valve replacement (TAVR) expands into younger patients with longer life expectancy, the definition of a successful procedure needs to grow with it. A July 2026 international position statement identified this trend as a reason for greater focus...
On 2 October 2026, Novartis agreed to license an autoimmune candidate from Abogen for $575 million upfront. Abogen’s release said milestones could add up to about $7.2 billion if every option is exercised. Many headlines led with the combined figure of about $7.8...
Vaxcyte reported positive topline results from OPUS-1 on Monday 5 October 2026. The pivotal adult Phase 3 tested VAX-31, the company’s 31-valent pneumococcal conjugate vaccine. It is the first of three adult Phase 3 trials to report. The release was datelined San...
Novartis has licensed an mRNA-encoded T-cell engager from Abogen Biosciences of Suzhou, China. Abogen announced the licensing and option agreement through PR Newswire on Friday 2 October 2026. The upfront payment is 575 million US dollars. Milestones could add up to...
Complement-targeted drug development requires more than measuring individual proteins. Integrating functional hemolysis assays, carefully selected serum or plasma samples, and multiplex biomarker analysis can provide a more reliable picture of complement activity,...
In the first half of 2026, China’s innovative drug licensing deals reached $106.3bn, according to VBInsight data published by VCBeat. That total covers inbound and outbound deals. That compares with $135.7bn for the whole of 2025 on the same provider’s count. This...
The oncology field has made remarkable progress over the past two decades in defining the molecular and immunological drivers of cancer. Modern targeted approaches and immunotherapies have transformed outcomes for many patients, particularly when treating primary or...
Telix Pharmaceuticals has agreed to buy ITM Isotope Technologies Munich SE. Telix describes ITM as the largest supplier of lutetium-177 by revenue. The deal places that radioisotope supply business inside a therapeutics developer. Telix issued the joint announcement...
For RNA therapeutics, encapsulation efficiency is a formulation metric—not proof of functional delivery. The development of lipid nanoparticle (LNP) RNA delivery systems is entering a more demanding phase. As nucleic acid therapeutics expand beyond conventional siRNA...
Collagen bioinks have to satisfy two very different demands. They need to behave predictably during printing, and once the printing stops they must also provide an environment in which cells can organise and begin behaving like tissue. However, it’s typically the...
Abstract Radial immunodiffusion (RID) can look almost outdated beside ELISA, multiplex assays, and automated analytical platforms. Yet that apparent simplicity may be exactly why the method still deserves attention. RID offers a direct, visually interpretable way to...
What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...